Morgan Stanley’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.7M | Buy |
2,167,121
+700,261
| +48% | +$7.98M | ﹤0.01% | 2593 |
|
|
2025
Q1 | $17.4M | Sell |
1,466,860
-98,106
| -6% | -$1.17M | ﹤0.01% | 2831 |
|
|
2024
Q4 | $29.5M | Sell |
1,564,966
-313,598
| -17% | -$5.91M | ﹤0.01% | 2355 |
|
|
2024
Q3 | $42.2M | Sell |
1,878,564
-111,136
| -6% | -$2.5M | ﹤0.01% | 1993 |
|
|
2024
Q2 | $41.5M | Sell |
1,989,700
-541,099
| -21% | -$11.3M | ﹤0.01% | 1933 |
|
|
2024
Q1 | $37.2M | Sell |
2,530,799
-3,739,275
| -60% | -$55M | ﹤0.01% | 2044 |
|
|
2023
Q4 | $64.7M | Buy |
6,270,074
+6,016,661
| +2,374% | +$62.1M | ﹤0.01% | 2179 |
|
|
2023
Q3 | $1.99M | Buy |
253,413
+44,316
| +21% | +$348K | ﹤0.01% | 4403 |
|
|
2023
Q2 | $2.09M | Sell |
209,097
-43,815
| -17% | -$438K | ﹤0.01% | 4395 |
|
|
2023
Q1 | $2.25M | Sell |
252,912
-147,510
| -37% | -$1.31M | ﹤0.01% | 4385 |
|
|
2022
Q4 | $4.4M | Sell |
400,422
-80,120
| -17% | -$880K | ﹤0.01% | 3866 |
|
|
2022
Q3 | $6.26M | Sell |
480,542
-101,563
| -17% | -$1.32M | ﹤0.01% | 3478 |
|
|
2022
Q2 | $7.38M | Sell |
582,105
-98,754
| -15% | -$1.25M | ﹤0.01% | 3393 |
|
|
2022
Q1 | $9.54M | Buy |
680,859
+594,538
| +689% | +$8.33M | ﹤0.01% | 2959 |
|
|
2021
Q4 | $2.5M | Sell |
86,321
-53,252
| -38% | -$1.54M | ﹤0.01% | 4400 |
|
|
2021
Q3 | $4.18M | Sell |
139,573
-303,465
| -68% | -$9.09M | ﹤0.01% | 3923 |
|
|
2021
Q2 | $11.8M | Buy |
443,038
+348,995
| +371% | +$9.26M | ﹤0.01% | 2794 |
|
|
2021
Q1 | $2.92M | Buy |
94,043
+85,246
| +969% | +$2.65M | ﹤0.01% | 3951 |
|
|
2020
Q4 | $289K | Buy |
8,797
+7,069
| +409% | +$232K | ﹤0.01% | 5393 |
|
|
2020
Q3 | $60K | Buy |
+1,728
| New | +$60K | ﹤0.01% | 5657 |
|